Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Double-Dummy, Randomized, Parallel Group Trial of SL650472 (Three Dose Regimens Versus Placebo and Cilostazol), for 24-Week Improvement of Walking Distance in Patients With Stage II Peripheral Arterial Disease Who Benefit From Optimal Prevention Strategy Including Clopidogrel

NCT00300339 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00300339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00300339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Double-Dummy, Randomized, Parallel Group Trial of SL650472 (Three Dose Regimens Versus Placebo and Cilostazol), for 24-Week Improvement of Walking Distance in Patients With Stage II Peripheral Arterial Disease Who Benefit From Optimal Prevention Strategy Including Clopidogrel
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
December 31, 2007
Enrollment
599 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

intermittent claudication